In the early 2000s, long-acting, once-daily insulin was approved, completely changing the experience of using insulin for people with diabetes. But science doesn't stand still. Now the FDA has approved weekly insulin. In this special episode of Diabetes Core Update, Neil Skolnik speaks with Athena Philis-Tsimikas, MD about this exciting development.

This special edition of Diabetes Core Update is sponsored with support from Lilly.

Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform.

Presented by:

-Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

-Athena Philis-Tsimikas, MD, Corporate Vice President of the Scripps Whittier Diabetes Institute and Diabetes Care Line at Scripps Health in San Diego, CA

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease.

This month, they discuss:

• Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277

• Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283

• Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767

• Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238

• Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063

• Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events

For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

In this special edition on Emerging Technologies for People with Diabetes our host, Dr. Neil Skolnik will discuss recent and future advances in technologies for people with diabetes. This special episode is supported by an independent educational grant from Seagrove Partners.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

Erik Veerhoef, Founder, President and CEO of Seagrove Partners